Historical Press Releases

2015

Soligenix Announces Recent Highlights and Second Quarter 2015 Financial Results

Princeton, NJ – August 12, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

Princeton, NJ – August 19, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS

Princeton, NJ – August 27, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Princeton, NJ – August 31, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix to Present at the 3rd Annual BioNJ CEO Summit

Princeton, NJ – October 5, 2015 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...

Show per page